Literature DB >> 9098274

A ten-year follow-up on a prospective, randomized trial of postoperative corticosteroids after trabeculectomy.

S V Araujo1, G L Spaeth, S M Roth, R J Starita.   

Abstract

PURPOSE: Patients prospectively enrolled in a clinical trial to evaluate the effect of corticosteroid use after guarded filtration procedure (trabeculectomy) were re-evaluated after 10 years to determine whether (1) there were differences in intraocular pressure (IOP) level and stability of glaucoma between treated and nontreated eyes, (2) surgery had altered the clinical course of the patients, and (3) there was any relation between level of IOP and glaucoma control.
METHODS: Forty-six eyes of 35 patients were evaluated individually. Stabilization/ progression of glaucoma was established based on IOP, clinical evaluation of visual fields, and stereoscopic analysis of disc using ophthalmoscopy and photography.
RESULTS: The nonsteroid-treated eyes underwent more additional glaucoma surgeries, were treated with more glaucoma medicines, and had higher IOPs. Glaucoma was stabilized in 82.8% of the steroid-treated eyes and 67% of the nonsteroid-treated eyes. There was a direct correlation between level of IOP and stabilization of optic nerve and visual field in both groups.
CONCLUSION: The use of corticosteroids after guarded filtration procedure was correlated with better glaucoma control. Patients with lower IOPs were more likely to be stabilized than those with higher pressures.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9098274     DOI: 10.1016/s0161-6420(95)30797-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

1.  Postoperative flat anterior chamber: incidence, risk factors, and effect on the long-term success of trabeculectomy.

Authors:  Takeshi Ono; Kenya Yuki; Daisuke Shiba; Takayuki Abe; Keisuke Kouyama; Kazuo Tsubota
Journal:  Jpn J Ophthalmol       Date:  2013-08-30       Impact factor: 2.447

2.  Decorin and suramin inhibit ocular fibroblast collagen production.

Authors:  H Mietz; P Chévez-Barrios; M W Lieberman; M Wendt; R Gross; S F Basinger
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

3.  Long-term results of trabeculectomy in eyes that were initially successful.

Authors:  J T Wilensky; T C Chen
Journal:  Trans Am Ophthalmol Soc       Date:  1996

4.  Risk factors for failures of trabeculectomies performed without antimetabolites.

Authors:  H Mietz; B Raschka; G K Krieglstein
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

5.  Changes in the morphology of the hyperemic blebs in eyes undergone trabeculectomy with mitomycin C after injection of triamcinolone acetonide during one-year follow-up.

Authors:  Zakieh Vahedian; Ghasem Fakhraie; Marzye Faraji; Seyed Mehdi Tabatabaei
Journal:  Int Ophthalmol       Date:  2021-06-25       Impact factor: 2.031

6.  A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis).

Authors:  Mark Brian Sherwood
Journal:  Trans Am Ophthalmol Soc       Date:  2006

7.  Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma.

Authors:  Kazuyuki Hirooka; Fumio Shiraga
Journal:  Clin Ophthalmol       Date:  2007-09

8.  Trabeculectomy with intraoperative retrobulbar triamcinolone acetonide.

Authors:  Malik Y Kahook; Larissa Camejo; Robert J Noecker
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  Suramin inhibits wound healing following filtering procedures for glaucoma.

Authors:  H Mietz; P Chévez-Barrios; R M Feldman; M W Lieberman
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

10.  Intensified postoperative care versus conventional follow-up: a retrospective long-term analysis of 177 trabeculectomies.

Authors:  Dirk Marquardt; Wolfgang E Lieb; Franz Grehn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-26       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.